[Established oneself the detection of serum prostate specific antigen and application in clinical practice]

Serum prostate specific antigen (PSA)-the biotinavidin enzyme immunoassay (BA-ELISA) was established and used in clinical practice. We assayed serum PSA in normal control and prostatic patients. If 10ng/ml was taken as the cutoff value, the positive rate of prostatic cancer was 62.96%. The results of determination showed: PSA serum levels of patients with complicated BPH (acute prostatitis and chronic prostatitis) were conspicuously higher than the noncomplicated BPH. In the BPH group, we simultaneously detected serum levels of PSA by BA-ELISA and Tandem-E PSA Immuno Enzy Metric Assay. The results suggested BA-ELISA technique is more sensitive and more economical than Tandem-E PSA Immuno Enzy Metric Assay for clinical use.